Nectar Lifesciences Ltd. shares fell nearly 20% to ₹18.60 after announcing the sale of its API and formulations business to Ceph Lifesciences for ₹1,270 crore. The deal aims to streamline operations and unlock shareholder value while the stock remains down over 26% in the past year.